<DOC>
	<DOCNO>NCT00661713</DOCNO>
	<brief_summary>The propose study aim ass antibody response short-term persistence Novartis Meningococcal B Vaccine one , two three dos evaluate optimal vaccination schedule adolescent population .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Novartis Meningococcal B Recombinant Vaccine Administered Healthy Adolescents According Different Vaccination Schedules</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 ) 1117 year age inclusive give write assent whose parent legal guardian give write informed consent time enrollment ; 2 ) available visit schedule study ( i.e. , plan leave area end study period ) ; 3 ) good health determine outcome medical history , physical examination clinical judgment investigator . 1 . History meningococcal B vaccine administration ; 2 . Current previous , confirm suspected disease cause N. meningitidis ; 3 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment ; 4 . Significant acute chronic infection within previous 7 day fever ( defined axillary temperature ≥38°C ) within previous day ; 5 . Antibiotics within 6 day prior enrollment ; 6 . Pregnancy nursing ( breastfeed ) mother ; 7 . Females childbearing age use plan use acceptable birth control measure , 7 month duration study . Oral , inject implanted hormonal contraceptive , diaphragm , condom , intrauterine device sexual abstinence consider acceptable form birth control . If sexually active subject must use one accepted birth control method least two month prior study entry ; 8 . Any serious chronic progressive disease ( e.g. , neoplasm , diabetes , cardiac disease , hepatic disease , progressive neurological disease seizure disorder ; autoimmune disease , HIV infection AIDS , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) . 9 . Known suspected impairment/alteration immune system , immunosuppressive therapy , include use corticosteroid immunosuppressive dos chronic use inhale highpotency corticosteroid within previous 60 day . [ Use topical corticosteroid administer study limited area ( i.e. , eczema knee face elbow ) body allow ] ; immunostimulants ; 10 . Receipt blood , blood product and/or plasma derivative , parenteral immunoglobulin preparation within previous 90 day ; 11 . History severe allergic reaction previous vaccination hypersensitivity vaccine component ; 12 . Receipt intent immunize vaccine ( ) within 30 day prior ( 60 day live viral vaccine ) throughout study period ( exception : licensed fluvaccine administer within 14 day prior enrollment ; routine vaccine administration may administer blood draw Study Month 7 ) ; 13 . Participation another clinical trial within last 90 day plan study ; 14 . Family member household member research staff ; 15 . Any condition opinion investigator and/or Regional MD may interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>Neisseria meningitidis serogroup B</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
	<keyword>adolescent</keyword>
</DOC>